)
Visual
earnings real time
Nxera Pharma (4565) investor relations material
Nxera Pharma R&D Day summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.R&D Day summary18 Nov, 2025
Pipeline overview and program updates
R&D portfolio streamlined to focus on obesity, metabolism, and endocrinology, with 80% of programs in these areas; non-priority programs are being partnered or terminated.
NXE'149 (schizophrenia) completed phase I with a licensing decision from Boehringer Ingelheim expected; NXE'732 (IBD/solid tumors) investment halted or seeking partners, with phase II expansion ongoing.
Seven new proprietary obesity programs launched, advancing next-generation oral therapies for weight management and co-morbidities.
In-house and partnered programs, such as Direclidine (schizophrenia), ORX750 (narcolepsy), and NXE'744 (IBD), are advancing in late-stage clinical trials.
Partnered pipeline includes collaborations with major pharma (Neurocrine, Pfizer, Centessa, AbbVie, Lilly) and co-owned companies, spanning neurology, immunology, and metabolic indications.
Clinical trial data and development milestones
NXE'732 (EP4 antagonist) showed >30% tumor reduction and strong target engagement in phase I/II; phase IIa expansion ongoing for multiple cancer types.
NXE'149 (GPR52 agonist) completed phase I with strong safety and PK profile; phase IB data expected by year-end or Q4 2025, with a EUR60m license decision pending.
NXE'744 (EP4 agonist) completed FTIH SAD/MAD studies with no concerning adverse events; UC patient cohort underway, readout expected Q1 2026.
ORX750 (OX2R agonist, Centessa) demonstrated significant efficacy in NT1, NT2, and IH; registrational phase III to initiate Q1 2026.
Neurocrine's muscarinic platform, designed using NxWave™, has five clinical-stage programs for neuropsychiatric disorders, with multiple phase II/III trials ongoing.
R&D strategy and innovation priorities
Focused on best-in-class, de-risked biology targets, especially in obesity and metabolic diseases, aiming for rapid early efficacy signals.
NxWave platform underpins discovery of novel oral small molecules, targeting GLP-1, GIP, amylin, and others for differentiated patient outcomes.
Early-stage research spending prioritized over costly early clinical development, with aggressive timelines for candidate selection.
R&D cost compression and resource reallocation to maximize returns and accelerate discovery.
Renewed R&D focus under new CSO Dr. Patrik Foerch, emphasizing disciplined portfolio decision-making and accelerated program progression.
Impact of 80% R&D focus on obesity/metabolism
Drivers of JPY 3.5B UK R&D cost reduction
Future strategy for major discovery collaborations
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nxera Pharma earnings date
Q4 202513 Feb, 2026
Next Nxera Pharma earnings date
Q4 202513 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Sosei Group Corporation, also known as Sosei Heptares, is a biopharmaceutical company that specializes in the development of drugs using its proprietary G protein-coupled receptor (GPCR) targeted StaR technology and structure-based drug discovery (SBDD) platform. The company's product lineup includes medicines such as Ultibro, Seebri, Enerzair, Breezhaler, Pivlaz, and Oravi. Sosei Group Corporation is headquartered in Chiyoda-ku, Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage